权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Multiscale mechanobiology of right ventricular failure

右心室衰竭的多尺度力学生物学

基本信息

批准号：
10657570
负责人：
Anthony J. BAKER
金额：
$ 69.65万
依托单位：
UNIVERSITY OF CALIFORNIA-IRVINE
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-07-01 至 2025-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10657570
关键词：
Adult Affect Apoptosis Biological Assay Blood capillaries Cardiac Cardiac Output Cause of Death Computer Models Data Data Set Disease Exposure to Failure Fibrosis Functional disorder Generations Goals Hand Heart Human Human Rights Hypertrophy Impairment Individual Kinetics Left Measurement Measures Mechanics Microfilaments Mitochondria Modeling Morbidity - disease rate Muscle Cells Myocardial tissue Myocardium Nature Necrosis Organ Organelles Organism Oxidative Stress Patients Phenotype Protocols documentation Public Health Pulmonary artery structure Rattus Relaxation Respiration Right ventricular structure Rodent Rodent Model Sampling Severities Techniques Testing Time Tissues Ventricular Whole Organism Work cardiovascular collapse constriction coronary fibrosis crosslink effective therapy exercise capacity exercise intolerance experience experimental study human disease improved in vivo mortality multi-scale modeling novel predictive modeling preservation pressure prevent pulmonary arterial hypertension pulmonary vascular remodeling right ventricular failure

项目摘要

SUMMARY/ABSTRACT Computational modeling approaches are rarely applied to the right ventricle even though, like left ventricular failure (LVF), right ventricular failure (RVF) is multifactorial, multiscale and causes significant morbidity and mortality. In comparison to LVF, RVF is understudied with the important consequence that no RV-specific therapies exist. Computational multi-scale modeling offers a unique opportunity to integrate dysfunction manifest at multiple scales: at the organelle level, there are impairments of mitochondria, Ca2+- handling, and myofilament function; at the tissue level, there is myocyte necrosis, apoptosis, fibrosis and capillary rarefaction; at the organ level, hypertrophy and dilation; and at the organism level, exercise intolerance. Moreover, computational modeling is ideally suited to answering the question: what are the relative contributions from abnormalities at multiple scales to the overall phenotype of RVF? We propose to answer this question with a data-driven, multiscale, computational modeling approach. Beginning with an existing mitochondrial kinetic computational model fit to healthy and RVF mitochondrial function, we will predict the emergence of dysfunction at the tissue-level. Then, fitting a myocardial tissue computational model to healthy and RVF passive and active mechanics, we will predict emergence of dysfunction at the organ-level. Finally, by adapting an existing biventricular mechanics computational model to healthy and RVF pressure-volume dynamics, we will predict the emergence of dysfunction at the organism-level, i.e., exercise intolerance. Model assumptions and predictions will be driven-by and tested against experimental data collected using state-of-the-art techniques at the organelle-, tissue-, organ-, and organism-scales at multiple time points in an established rat model of RVF. Finally, we will use our data-driven computational modeling approach to confirm the human disease relevance of mechanisms of RVF found in rodent using our state-of-the- art experimental techniques on human failing and nonfailing myocardium. Our specific aims are: Aim 1: Determine the drivers of systolic dysfunction in RVF. We hypothesize that the major driver of systolic dysfunction in RVF is impaired mitochondrial generation of ATP leading to impaired contraction of cardiac myofilaments. We will test this hypothesis with scale-specific models and multi-scale experimental data collected from rats with RVF. Aim 2: Determine the drivers of diastolic dysfunction in RVF. We hypothesize that diastolic dysfunction in RVF is driven by fibrosis and impaired myofilament relaxation. We will test this hypothesis with scale-specific models and multi-scale experimental data collected from rats with RVF. Aim 3: Determine the drivers of systolic and diastolic function in human RVF. Key predictions of organelle- and tissue-scale structural and functional drivers of RVF will be tested with multiscale modeling validated with state-of-the-art measurements at these scales in non-failing and failing human heart tissues.

摘要/文摘